iRadimed (NASDAQ:IRMD) Issues Quarterly Earnings Results, Hits Expectations

iRadimed (NASDAQ:IRMD) issued its earnings results on Friday. The medical equipment provider reported $0.55 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.55, FiscalAI reports. The firm had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $23.47 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%.

Here are the key takeaways from iRadimed’s conference call:

• Record third-quarter results included revenue of $24.2 million, up 14% year over year and 18% sequentially, while GAAP EPS rose to $0.51 from $0.43 a year ago.
• The 3870 MR IV pump launch is gaining traction, with more than 300 systems shipped in Q3, record pump and monitor bookings, and a growing backlog. Management estimates an opportunity of more than 10,000 replacement channels, with the new pump carrying an approximately 23%-25% higher ASP than the older model.
• The company reduced its 2026 revenue outlook to $91.7 million-$93.2 million from $91 million-$96 million and lowered its GAAP EPS range to $1.90-$1.94 from $1.90-$2.05, citing the need to moderate production ramping to protect quality.
• Manufacturing efficiencies lifted gross margin to 76% sequentially, and management expects further improvement in Q4 and potentially a return to 77%-78% or higher in 2027. Management also projected double-digit, potentially upper-teens, revenue growth in 2027 and ended the quarter with $63.3 million in cash while declaring a $0.20 quarterly dividend.

iRadimed Trading Down 10.6%

NASDAQ:IRMD opened at $76.68 on Friday. The firm has a market capitalization of $980.74 million, a price-to-earnings ratio of 41.01 and a beta of 0.91. iRadimed has a 1-year low of $76.35 and a 1-year high of $107.90. The business’s fifty day moving average price is $85.66 and its 200 day moving average price is $92.69.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Record revenue and year-over-year growth: Third-quarter revenue reached $24.2 million, up 14% from the prior-year period and 18% sequentially. Revenue also exceeded the FactSet consensus estimate of $23.5 million. iRadimed Third Quarter 2026 Financial Results
• Positive Sentiment: Improved profitability: GAAP diluted EPS was $0.51, while non-GAAP diluted EPS was $0.55, up from $0.41 and $0.47, respectively, in the second quarter. Non-GAAP EPS matched analysts’ consensus estimate, while the company maintained a 26.7% net margin and 23.45% return on equity. IRadimed Q3 Earnings and Outlook
• Positive Sentiment: Potential production acceleration: Management expects fourth-quarter revenue of $25 million to $26.5 million and is targeting more than 50% sequential growth in output for its MRidium 3870 infusion pump, supporting a potential path toward a $100 million annual revenue run rate. iRadimed Q4 Revenue Outlook

Insider Buying and Selling

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares in the company, valued at approximately $1,691,994.21. This trade represents a 6.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 34.60% of the company’s stock.

Analysts Set New Price Targets

IRMD has been the topic of a number of recent research reports. Needham & Company LLC began coverage on iRadimed in a report on Tuesday, September 22nd. They issued a “hold” rating on the stock. Weiss Ratings raised iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 16th. Finally, Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, iRadimed presently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.